Clinical trial
The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive…
NCT00366301 · Brigham and Women's Hospital, Other · Terminated
Key facts
| NCT number | NCT00366301 |
|---|---|
| Title | The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes |
| Official title | The LANCET Trial: A Randomized Clinical Trial of Lantus for C-reactive Protein Reduction in Early Treatment of Type 2 Diabetes |
| Lead sponsor | Brigham and Women's Hospital, Other |
| Collaborators | Sanofi Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Insulin glargine injection, metformin, Placebo pill |
| Enrollment | 500 |
| Start date | Aug 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Aug 21, 2006 |
| Last update posted | Nov 25, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: